UK markets open in 1 hour 56 minutes

GRFS Feb 2025 4.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.49000.0000 (0.00%)
As of 12:08PM EDT. Market open.
Full screen
Previous close0.4900
OpenN/A
Bid0.0000
Ask0.0000
Strike4.00
Expiry date2025-02-21
Day's range0.4900 - 0.4900
Contract rangeN/A
VolumeN/A
Open interestN/A
  • Reuters

    Spanish drugmaker Grifols appoints new finance chief as shake-up continues

    The accounting accusations in a report by Gotham City Research last January sparked a slump in the Grifols share price. Grifols has denied the accusations and also filed a lawsuit in the United States against the fund and its founder. Srinivasan will start on Sept. 16, succeeding Alfredo Arroyo, who is retiring after 17 years at the company, Grifols said in Thursday's filing to the Spanish stock market regulator.

  • Reuters

    Unit of Grifols shareholder Scranton reaches debt refinancing deal

    Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its units. Spanish drugmaker Grifols' market value has shed billions of euros since short-sheller Gotham City Research released a report in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.

  • GlobeNewswire

    Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

    Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote